3[3]Negrier S.Long-term follow-up of patients with metastic renal cell carcinoma treated with intravenous recombinant IL-2 in Europe[J].Cancer J Sci Am,2000,2,6(1):93-98.
3Negrier S. Long-term follow-up of patients with metastic renal cell carcinoma treated with intravenous recombinant IL-2 in Europe[J]. Cancer J Sci Am, 2000,2,6(Suppl 1) :S93-8.
4Bukowski R M. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma[J]. Semin Oncol, 2000,27 : 204 - 212.
5Atzpodien J, Kirchner H, Illiger H J, et al. IL-2 in combination with IFN-alpha and 5-FU verse tamoxifen in metastatic renal cell carcinoma: long-term result of a controlled randomised clinical trial [J]. Br J Cancer,2001,85:1130-1136.
6Gez E, Rubinov R, Gaitini D, et al. Interleukin-2, interferon-alpha,5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase 2 study: the experience of Rambam and Lin Medical Centers, 1996-2000[J]. Cancer, 2002, 95:1644-1649.
7McDermott D F, Regan M M, Clark J I, et al. Randomized phase Ⅲ trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patientswith metastatic renal cell carcinoma[J]. J Clin Oncol,2005,23(1) :133-141.
8Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer[J]. Cochrane Database Syst Rev,2005,25,(1) :CD001425.
9Hernberg M, Virkkunen P, Bono P, et al. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatie renal cell carcinoma[J]. J Clin Oncol, 2003,21 (20) : 3770- 3776.
10May M,Helke C,Bock M,et al. Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. Aretrospective study comparing interferon-alpha-2 a/vinblastine versusinterferon-alpha-2a/interleukin-2/5-fluorouracil[J]. Urologe A, 2004, 43 (9):1111-1119.
